Overview

DC Vaccine in Pancreatic Cancer

Status:
Recruiting
Trial end date:
2021-10-01
Target enrollment:
0
Participant gender:
All
Summary
This research study is designed to evaluate the effects of a dendritic cell (kind of white blood cell) vaccine for pancreatic cancer.
Phase:
Phase 1
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
University of Pennsylvania
Treatments:
Vaccines
Criteria
Inclusion Criteria:

- Pathologically-confirmed KRAS(G12D-), KRAS(G12V-), KRAS(G12R-) or KRAS(G12C-mutated)
pancreatic ductal adenocarcinoma who are at high risk of relapse and have no evidence
of disease.

- Expression of one or more of the following HLA class I alleles: HLA-A02, HLA-A03,
HLA-A11, HLA-B07 and HLA-C08.

- Male or female, age 18+

- ECOG performance status 0-1

- Certain required laboratory values, performed within 14 days prior to consent

- Subjects of reproductive potential must agree to use a medically accepted birth
control method during the trial and for at least two months following the trial.

- Provide written informed consent

Exclusion Criteria:

- Prior treatment with more than two lines of cytotoxic chemotherapy. Radiotherapy is
not considered a line of therapy.

- Prior malignancy (except non-melanoma skin cancer) within 3 years.

- Pregnant or nursing women.

- Concurrent treatment with systemic immunosuppressants, including corticosteroids (e.g
prednisone), calcineurin inhibitors (e.g tacrolimus, cyclosporine), antiproliferative
agents (e.g mycophenolate mofetil, azathioprine) within 2 weeks of eligibility
confirmation. Local (inhaled or topical) steroids or replacement dose prednisone (≤ 10
mg daily) are permitted.

- Known chronic viral infections including hepatitis B, hepatitis C, and HIV.

- Known allergy to eggs.

- Prior history of uveitis or autoimmune inflammatory eye disease.

- Uncontrolled intercurrent illness.

- Any condition that, in the opinion of the investigator, would interfere with
evaluation of the investigational product or interpretation of subject safety or study
results.